CN Patent

CN115175902B — 一类用作激酶抑制剂的化合物及其应用

Assigned to Deuracor Therapeutic Inc · Expires 2024-07-26 · 2y expired

What this patent protects

式Ⅰ所示的激酶抑制剂的化合物或其药学上可以接受的盐、溶剂化物或前药。该化合物对EGFR和Her2外显子20插入突变、EGFR外显子19缺失和外显子21的L858R点突变具有良好的抑制活性。

USPTO Abstract

式Ⅰ所示的激酶抑制剂的化合物或其药学上可以接受的盐、溶剂化物或前药。该化合物对EGFR和Her2外显子20插入突变、EGFR外显子19缺失和外显子21的L858R点突变具有良好的抑制活性。

Drugs covered by this patent

mobocertinib-succinate (MOBOCERTINIB SUCCINATE)

Patent Metadata

Patent number: CN115175902B
Jurisdiction: CN
Classification: —
Expires: 2024-07-26
Drug substance claim: No
Drug product claim: No
Assignee: Deuracor Therapeutic Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.